MB Venture Partners
Gary Stevenson, Co-Founder and Managing Partner
Gary Stevenson co-founded MB Venture Partners in 2001 after six years in healthcare investment banking and equity research. At MBVP, he has raised $120 million in committed capital to four funds and invested in more than 50 start-ups, most of which are focused on product solutions for musculoskeletal disease. He also spent seven years in a variety of general management roles with Abbott Laboratories. Gary holds an undergraduate degree in accounting from the University of Missouri. He also received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. He is a certified public accountant and a chartered financial analyst. Gary is a board member or observer for several MBVP portfolio companies. Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical have each acquired MBVP-funded start-ups. This will be his 18th year to host the MNVC.
Kyle Rose, Managing Director
Kyle Rose has been a member of Canaccord Genuity’s medical technology research team since 2010 and is the senior analyst responsible for covering the orthopedics, diabetes, aesthetics and ENT sectors. Prior to joining Canaccord Genuity, Kyle worked as an associate product manager for Zimmer Biomet (formerly Biomet Microfixation), a medical device manufacturer focusing on the craniomaxillofacial, neurosurgery, and cardiothoracic markets. Kyle holds an MBA from the Kellogg School of Management at Northwestern University as well as a BA from the University of Michigan.
Dennis O’Dowd, CEO
Suzanne Maher, PhD – Co-Founder
Tony Chen, PhD – Director of Scientific Affairs
AGelity Biomechanics is a medical device company developing innovative cartilage repair products that look, feel and act like native tissues. The Company’s first product, AGelity-OCI, is targeting cartilage damage in the knee, a very large and growing market lacking a true off-the-shelf solution. AGelity is the first spin-out from the Hospital for Special Surgery (“HSS”) and has a strong technical team of clinicians, scientists, and management working together to address the lack of reliable and early stage treatments for cartilage repair in healthy adults with injury-induced osteoarthritis. The Company has been largely funded through non-dilutive extramural grants from the National Institutes of Health, including the prestigious Small Business Innovation Research Phase I and II grants. In total the Company has secured $2.2 million of non-dilutive grants and awards to fund the development of its core technology, AGelity-OCI.
IlluminOss Medical, Inc.
Bob Rabiner, Chief Technical Officer
Mike Mogul, Chairman
IlluminOss Medical, Inc. is a privately held, commercial-stage medical device company offering a unique, minimally invasive technology for the repair and stabilization of fractures in poor quality weakened bone; particularly applicable for osteoporotic and pathologically compromised bone. The IlluminOss system utilizes a light-curable liquid monomer which is infused and contained within a conformal balloon sized to the patient’s anatomy and then illuminated with visible blue light converting the liquid to a strong hardened polymer, creating a patient-conforming intramedullary implant. The cured implant conforms to the shape of the patient’s intramedullary canal, providing rapid strength and stability to the compromised bone. Designed as a stand-alone implant, however should supplemental fixation devices be needed, they can be placed anywhere along the implant. The speed, simplicity and minimally invasive procedure has permitted the majority of patients treated with IlluminOss to return to their daily living activities far sooner and with less use of post-operative pain medications. Used in over 4000 patients in Europe, IlluminOss has been recently launched in the United States for general trauma use. The IlluminOss system is both FDA-cleared and CE marked for a wide variety of anatomical sites, with further indications pending. IlluminOss is headquartered in East Providence, RI.
Bryan Lord, Co-Founder, CEO
Dave Carey, Chief Commercial Officer
Pristine Surgical is dedicated to improving the surgical episode for patient, surgeon and center in endoscopic procedures via our single-use digital visualization platform. We provide consistently clear images with a brand-new endoscope, every time.
Richard Treadwell, President & CEO
Louie Fielding, COO and co-founder
Richard is an accomplished senior executive with more than 25 years of operating experience and a deep understanding of general management in healthcare. He has held functional leadership roles in marketing, business development, engineering and product development. As a founder of two Bay Area-based startups, he has demonstrated entrepreneurial acumen with fundraising, P&L and operating leadership. Richard has achieved consistent excellent results across a broad range of medical device therapeutic areas, including interventional cardiology at Biosensors International, cardiac surgery at Embol-X, pulse-oximetry at Nellcor, orthodontic support at Align Technology/General Orthodontic and otolaryngology at Aardvark Medical. Richard holds an MBA from The Wharton School at the University of Pennsylvania, as well as an MA in International Relations from the Johns Hopkins School of Advanced International Studies (SAIS) and a BS from Stanford University in Engineering (Product Design).